Title:Drug Delivery for Cancer Immunotherapy and Vaccines
VOLUME: 6 ISSUE: 4
Author(s):Cole J. Batty, Pamela Tiet, Eric M. Bachelder and Kristy M. Ainslie*
Affiliation:Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, The University of North Carolina at Chapel Hill, Chapel Hill, NC
Keywords:Adjuvant, antigen, cytokine, dendritic cells, lymph nodes, microparticle, nanoparticle.
Abstract:Cancer cells are able to avoid immune surveillance and exploit the immune system to
grow and metastasize. With the development of nano- and micro-particles, there has been a growing
number of immunotherapy delivery systems developed to elicit innate and adaptive immune responses
to eradicate cancer cells. This can be accomplished by training resident immune cells to recognize
and eliminate cells with tumor-associated antigens or by providing external stimuli to enhance tumor
cell apoptosis in the immunosuppressive tumor microenvironment (TME). In this review we will focus
on nano- and micro-particle (NP and MP) based immunotherapies and vaccines used to elicit a
potent and sustained antitumor immune response.
